Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 163

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Apixaban for treatment of embolic stroke of undetermined source (ATTICUS randomized trial): Rationale and study design

Open access
Geisler, Tobias, Poli, Sven, Meisner, Christoph, Schreieck, Juergen, Zuern, Christine S, Nägele, Thomas, Brachmann, Johannes, Jung, Werner, Gahn, Georg, Schmid, Elisabeth, Bäezner, Hansjörg, Keller, Timea, Petzold, Gabor C, Schrickel, Jan-Wilko, Liman, Jan, Wachter, Rolf, Schön, Frauke, Schabet, Martin, Lindner, Alfred, Ludolph, Albert C, Kimmig, Hubert, Jander, Sebastian, Schlegel, Uwe, Gawaz, Meinrad, Ziemann, Ulf · 2017 · International Journal of Stroke

Abstract

Rationale: Optimal secondary prevention of embolic stroke of undetermined source is not established. The current standard in these patients is acetylsalicylic acid, despite high prevalence of yet undetected paroxysmal atrial fibrillation. Aim: The ATTICUS randomized trial is designed to determine whether the factor Xa inhibitor apixaban administered within 7 days after embolic stroke of undetermined source, is superior to acetylsalicylic acid for prevention of new ischemic lesions documented by brain magnetic resonance imaging within 12 months after index stroke. Design: Prospective, randomized, blinded, parallel-group, open-label, German multicenter phase III trial in approximately 500 patients with embolic stroke of undetermined source. A key inclusion criterion is the presence or the planned implantation of an insertable cardiac monitor. Patients are 1:1 randomized to apixaban or acetylsalicylic acid and treated for a 12-month period. It is an event-driven trial aiming for core-lab adjudicated primary outcome events. Study outcomes: The primary outcome is the occurrence of at least one new ischemic lesion identified by axial T2-weighted FLAIR magnetic resonance imaging and/or axial DWI magnetic resonance imaging at 12 months when compared with the baseline magnetic resonance imaging. Key secondary outcomes are the combination of recurrent ischemic strokes, hemorrhagic strokes, systemic embolism; combination of MACE including recurrent stroke, myocardial infarction, and cardiovascular death and combination of major and clinically relevant non-major bleeding defined according to ISTH, and change of cognitive function and quality of life (EQ-5D, Stroke Impact Scale). Discussion: Embolic stroke of undetermined source is caused by embolic disease and associated with a high risk of recurrent ischemic strokes and clinically silent cerebral ischemic lesions. ATTICUS will investigate the impact of atrial fibrillation detected by insertable cardiac monitor and the effects of early anticoagulation with apixaban compared with antiplatelet therapy with acetylsalicylic acid on the incidence of new ischemic lesion after embolic stroke of undetermined source.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1177/1747493016681019

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 163

Metadata

Authors
Geisler, T., Poli, S., Meisner, C., Schreieck, J., Zuern, C. S., Nägele, T., Brachmann, J., Jung, W., Gahn, G., Schmid, E., Bäezner, H., Keller, T., Petzold, G. C., Schrickel, J.-W., Liman, J., Wachter, R., Schön, F., Schabet, M., Lindner, A., Ludolph, A. C., Kimmig, H., Jander, S., Schlegel, U., Gawaz, M., & Ziemann, U.
Venue
International Journal of Stroke
Published
2016-11-23
Volume
12
Issue
9
Pages
985-990
ISSN
  • 1747-4930 (ISSN-L)
  • 1747-4949
OpenAlex
W2549334493
Cited by
163
References
9
FWCI
14.69
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Apixaban for treatment of embolic stroke of undetermined source (ATTICUS randomized trial): Rationale and study design. https://app.cochat.ai/papers/10.1177/1747493016681019
The paper
Geisler, T., Poli, S., Meisner, C., Schreieck, J., Zuern, C. S., Nägele, T., Brachmann, J., Jung, W., Gahn, G., Schmid, E., Bäezner, H., Keller, T., Petzold, G. C., Schrickel, J.-W., Liman, J., Wachter, R., Schön, F., Schabet, M., Lindner, A., . . . Ziemann, U. (2017). Apixaban for treatment of embolic stroke of undetermined source (ATTICUS randomized trial): Rationale and study design. International Journal of Stroke. https://doi.org/10.1177/1747493016681019

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.